Navigation Links
Opthea Signs Cell Line Development Commercial License Agreement with Selexis SA for Wet AMD Product
Date:1/13/2014

GENEVA, Jan. 13, 2014 /PRNewswire/ -- Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs announced today that Opthea Pty Ltd has entered into a commercial license agreement with Selexis covering the use of the CHO-M Cell Line and related technologies for the production of OPT-302 (formerly VGX-300), an Fc fusion protein for the treatment of wet Age-Related Macular Degeneration (wet AMD).

(Logo: http://photos.prnewswire.com/prnh/20120627/LA31604LOGO )

OPT-302 is a soluble form of human VEGFR-3 that blocks the activity of both VEGF-C and VEGF-D, which promote blood and lymphatic vessel formation and are implicated in the progression of eye disease.  OPT-302 is anticipated to enter Phase I clinical studies in early 2015 and is being developed by Opthea, a private, 100% owned subsidiary of Circadian Technologies (ASX:CIR; OTCQX:CKDXY) of Melbourne, Australia.

"Wet" (neovascular) AMD, is a disease characterized by the loss of vision in the middle of the visual field caused by degeneration of the central portion of the retina (the macula). Abnormal growth of blood vessels below the retina, and the leakage of fluid and protein from the vessels, cause retinal degeneration and leads to severe and rapid loss of vision.

"Selexis is excited about the collaboration with Opthea and looks forward to seeing OPT-302 progress to clinical studies in wet AMD patients," said Dr. Igor Fisch, CEO, Selexis SA. "The OPT-302 cell line demonstrates the power of our new technologies for the rapid generation of CHO cell lines expressing high yields of Fc fusion recombinant proteins. We look forward to continuing to work with Opthea."

"The productivity and speed of stable cell line generation with the SUREtechnology Platform™ is playing a key role in quickly progressing our candidate into clinical development," said Dr. Megan Baldwin, CEO of Opthea. "By leveraging the SUREtechnology Platform™, we were able to improve our titers by several fold."

About Opthea Pty. Ltd.

Opthea Pty Ltd is a private, 100% owned subsidiary of Circadian Technologies Limited based in Melbourne, Australia.  Opthea is developing novel biologic inhibitors of VEGF-C driven angiogenesis (blood vessel growth), lymphangiogenesis (lymphatic vessel growth) and vascular leakage for the treatment of ophthalmic diseases.

Opthea's compounds have broad utility in a range of eye diseases characterised by aberrant blood and/or lymphatic vessel growth, vascular leakage or edema, and inflammation, including wet AMD, diabetic macula edema, corneal neovascularisation and transplantation, and dry eye disease.

Opthea's lead compound, OPT-302, is a soluble receptor that specifically and potently blocks the activity of two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D that are involved in the progression of both retinal and corneal diseases. Opthea's lead program is the development of OPT-302 for the treatment of "wet" (neovascular) age-related macular degeneration (wet AMD).

For more information:

Please visit Opthea's website at www.opthea.com

Megan Baldwin, PhD
Chief Executive Officer
Opthea Pty Ltd
Tel: +61 (3) 9826 0399
Email: megan.baldwin@opthea.com

Opthea Media Enquiries – International
Lauren Glaser
The Trout Group LLC
Tel: +1 215 740 8468

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated cell lines being used in a variety of programs from drug discovery to late-stage clinical trials. 

For more information: 

Selexis Media Inquiries
Robert Meister
+1 602 953 1716
Email:  robert.meister@selexis.com

Visit http://www.selexis.com 
Follow us on Twitter @selexisSA 
Become a fan at www.facebook.com/SelexisSA


'/>"/>
SOURCE Selexis SA
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Pros and Cons of Adaptive Designs: A Leisurely Conversation Between a Clinician and Two Statisticians, New Webinar Hosted by Xtalks
2. InventHelp Inventor Designs an Improved Antibody Staining/Probing Tray (CCP-629)
3. Amedica Signs Agreement with Kyocera for Commercial Manufacture of Silicon Nitride Medical Devices
4. LayerBio, Inc. Announces Launch; Signs Option for Technology from MIT
5. Enerlabs Signs Agreement to Purchase 4th Laboratory
6. Russias International Biotechnology Center Generium Signs Access Agreement to Elseviers ScienceDirect and Embase
7. Samsung BioLogics Signs a Strategic Manufacturing Partnership with Roche
8. West Michigan Based Biomedical Company, Engineering 4 Life, Offers Services Using Patient Specific Data to Aid Medical Professionals and Provide Effective Medical Designs
9. Virginia Tech researchers publish study on jellyfish energy consumption that will improve bio-inspired robotic designs for Navy
10. Topical BioMedics, Inc., Signs on With CVS Pharmacy; Topricin® Foot Therapy Cream to be Carried in the Retailer’s Foot Care Section
11. Boyd "Rainmaker" Melson, Professional Athlete and Advocate for Spinal Cord Injury Treatment, Signs on as Advisory Board Member of Store-A-Tooth™ Dental Stem Cell Banking
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... -- This report analyzes the worldwide markets for Biostimulants in ... & Fulvic), Extract Based, and Others. The report also analyzes ... Turf, Row Crops, and Others. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts are provided ...
(Date:12/8/2016)...  Biotheranostics today announced that new data will ... Cancer Index (BCI) in identifying which patients with ... for disease recurrence and might benefit from extended ... advancing the understanding of the value of BCI ... inform decisions related to patient treatment. These data ...
(Date:12/8/2016)... OXFORD, England , December 8, 2016 /PRNewswire/ ... (OGT), das Unternehmen für Molekulargenetik, erweitert seine Palette ... SureSeq myPanel™ NGS Custom FH Panels, das ein ... Hypercholesterinämie (FH) ermöglicht. Das Panel bietet eine Erkennung ... Number Variations (CNV) mit einem einzigen kleinen Panel ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... in the World Technology Awards. uBiome is one of just six company finalists ... categories. , In addition to uBiome, companies nominated as finalists in this year’s ...
Breaking Biology Technology:
(Date:11/17/2016)... -- AIC announces that it has just released a new white paper authored by Zettar ... high speed data transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be ...
(Date:11/14/2016)... SANTA CLARA, Calif. , Nov. 14, ... of the biometric identification market, Frost & ... Global Frost & Sullivan Award for Visionary ... leading player in the biometric identification market ... a multi-modal verification solution for instant, seamless, ...
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
Breaking Biology News(10 mins):